Carfilzomib OS Benefit in Myeloma Highlighted in Published Findings
The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone extended overall survival for patients with relapsed or refractory multiple myeloma by nearly 8 months compared with lenalidomide and dexamethasone alone.
Source: OncLive